Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
Neuroendocrine Response to Exogenous Ghrelin Administration, Combined With Alcohol, in Heavy-Drinking Individuals: Findings From a Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study.

The international journal of neuropsychopharmacology

Farokhnia M, Abshire KM, Hammer A, Deschaine SL, Saravanakumar A, Cobbina E, You ZB, Haass-Koffler CL, Lee MR, Akhlaghi F, Leggio L.
PMID: 33560411
Int J Neuropsychopharmacol. 2021 Jul 14;24(6):464-476. doi: 10.1093/ijnp/pyab004.

BACKGROUND: Accumulating evidence has established a role for the orexigenic hormone ghrelin in alcohol-seeking behaviors. Accordingly, the ghrelin system may represent a potential pharmacotherapeutic target for alcohol use disorder. Ghrelin modulates several neuroendocrine pathways, such as appetitive, metabolic, and...

Cite
Farokhnia M, Abshire KM, Hammer A, et al. Neuroendocrine Response to Exogenous Ghrelin Administration, Combined With Alcohol, in Heavy-Drinking Individuals: Findings From a Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study. Int J Neuropsychopharmacol. 2021;24(6):464-476doi: 10.1093/ijnp/pyab004.
Farokhnia, M., Abshire, K. M., Hammer, A., Deschaine, S. L., Saravanakumar, A., Cobbina, E., You, Z. B., Haass-Koffler, C. L., Lee, M. R., Akhlaghi, F., & Leggio, L. (2021). Neuroendocrine Response to Exogenous Ghrelin Administration, Combined With Alcohol, in Heavy-Drinking Individuals: Findings From a Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study. The international journal of neuropsychopharmacology, 24(6), 464-476. https://doi.org/10.1093/ijnp/pyab004
Farokhnia, Mehdi, et al. "Neuroendocrine Response to Exogenous Ghrelin Administration, Combined With Alcohol, in Heavy-Drinking Individuals: Findings From a Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study." The international journal of neuropsychopharmacology vol. 24,6 (2021): 464-476. doi: https://doi.org/10.1093/ijnp/pyab004
Farokhnia M, Abshire KM, Hammer A, Deschaine SL, Saravanakumar A, Cobbina E, You ZB, Haass-Koffler CL, Lee MR, Akhlaghi F, Leggio L. Neuroendocrine Response to Exogenous Ghrelin Administration, Combined With Alcohol, in Heavy-Drinking Individuals: Findings From a Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study. Int J Neuropsychopharmacol. 2021 Jul 14;24(6):464-476. doi: 10.1093/ijnp/pyab004. PMID: 33560411; PMCID: PMC8278796.
Copy Download .nbib Format: NLM
Dataset for Phase I randomized clinical trial for safety and tolerability of GET 73 in single and repeated ascending doses including preliminary pharmacokinetic parameters.

Data in brief

Haass-Koffler CL, Goodyear K, Long VM, Tran HH, Loche A, Cacciaglia R, Swift RM, Leggio L.
PMID: 29214202
Data Brief. 2017 Sep 17;15:407-413. doi: 10.1016/j.dib.2017.09.018. eCollection 2017 Dec.

The data in this article outline the methods used for the administration of GET 73 in the first time-in-human manuscript entitled "Phase I randomized clinical trial for the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator...

Cite
Haass-Koffler CL, Goodyear K, Long VM, et al. Dataset for Phase I randomized clinical trial for safety and tolerability of GET 73 in single and repeated ascending doses including preliminary pharmacokinetic parameters. Data Brief. 2017;15:407-413doi: 10.1016/j.dib.2017.09.018.
Haass-Koffler, C. L., Goodyear, K., Long, V. M., Tran, H. H., Loche, A., Cacciaglia, R., Swift, R. M., & Leggio, L. (2017). Dataset for Phase I randomized clinical trial for safety and tolerability of GET 73 in single and repeated ascending doses including preliminary pharmacokinetic parameters. Data in brief, 15407-413. https://doi.org/10.1016/j.dib.2017.09.018
Haass-Koffler, Carolina L, et al. "Dataset for Phase I randomized clinical trial for safety and tolerability of GET 73 in single and repeated ascending doses including preliminary pharmacokinetic parameters." Data in brief vol. 15 (2017): 407-413. doi: https://doi.org/10.1016/j.dib.2017.09.018
Haass-Koffler CL, Goodyear K, Long VM, Tran HH, Loche A, Cacciaglia R, Swift RM, Leggio L. Dataset for Phase I randomized clinical trial for safety and tolerability of GET 73 in single and repeated ascending doses including preliminary pharmacokinetic parameters. Data Brief. 2017 Sep 17;15:407-413. doi: 10.1016/j.dib.2017.09.018. eCollection 2017 Dec. PMID: 29214202; PMCID: PMC5712048.
Copy Download .nbib Format: NLM
Corrigendum: Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study.

Alcohol and alcoholism (Oxford, Oxfordshire)

Haass-Koffler CL, Goodyear K, Zywiak WH, Leggio L, Kenna GA, Swift RM.
PMID: 29718153
Alcohol Alcohol. 2018 Jul 01;53(4):500. doi: 10.1093/alcalc/agy030.

No abstract available.

Cite
Haass-Koffler CL, Goodyear K, Zywiak WH, et al. Corrigendum: Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study. Alcohol Alcohol. 2018;53(4):500doi: 10.1093/alcalc/agy030.
Haass-Koffler, C. L., Goodyear, K., Zywiak, W. H., Leggio, L., Kenna, G. A., & Swift, R. M. (2018). Corrigendum: Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study. Alcohol and alcoholism (Oxford, Oxfordshire), 53(4), 500. https://doi.org/10.1093/alcalc/agy030
Haass-Koffler, Carolina L, et al. "Corrigendum: Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study." Alcohol and alcoholism (Oxford, Oxfordshire) vol. 53,4 (2018): 500. doi: https://doi.org/10.1093/alcalc/agy030
Haass-Koffler CL, Goodyear K, Zywiak WH, Leggio L, Kenna GA, Swift RM. Corrigendum: Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study. Alcohol Alcohol. 2018 Jul 01;53(4):500. doi: 10.1093/alcalc/agy030. PMID: 29718153; PMCID: PMC6016693.
Copy Download .nbib Format: NLM
An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder.

Psychopharmacology

Haass-Koffler CL, Perciballi R, Magill M, Loche A, Cacciaglia R, Leggio L, Swift RM.
PMID: 34731268
Psychopharmacology (Berl). 2021 Nov 03; doi: 10.1007/s00213-021-06008-1. Epub 2021 Nov 03.

RATIONALE: Previous work suggests that GET 73, a novel compound with putative activity on the metabotropic glutamate receptor subtype 5 (mGluR5), may represent a novel pharmacological treatment for alcohol use disorder (AUD).OBJECTIVE: In this study, we investigated the safety,...

Cite
Haass-Koffler CL, Perciballi R, Magill M, et al. An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder. Psychopharmacology (Berl). 2021;doi: 10.1007/s00213-021-06008-1.
Haass-Koffler, C. L., Perciballi, R., Magill, M., Loche, A., Cacciaglia, R., Leggio, L., & Swift, R. M. (2021). An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder. Psychopharmacology, . https://doi.org/10.1007/s00213-021-06008-1
Haass-Koffler, Carolina L, et al. "An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder." Psychopharmacology vol. (2021). doi: https://doi.org/10.1007/s00213-021-06008-1
Haass-Koffler CL, Perciballi R, Magill M, Loche A, Cacciaglia R, Leggio L, Swift RM. An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder. Psychopharmacology (Berl). 2021 Nov 03; doi: 10.1007/s00213-021-06008-1. Epub 2021 Nov 03. PMID: 34731268.
Copy Download .nbib Format: NLM
Protein Tyrosine Phosphatase β/ζ and Alcohol Use Disorder: A Commentary.

Alcoholism, clinical and experimental research

Haass-Koffler CL.
PMID: 32343842
Alcohol Clin Exp Res. 2020 Jun;44(6):1189-1191. doi: 10.1111/acer.14346. Epub 2020 May 18.

No abstract available.

Cite
Haass-Koffler CL. Protein Tyrosine Phosphatase β/ζ and Alcohol Use Disorder: A Commentary. Alcohol Clin Exp Res. 2020;44(6):1189-1191doi: 10.1111/acer.14346.
Haass-Koffler, C. L. (2020). Protein Tyrosine Phosphatase β/ζ and Alcohol Use Disorder: A Commentary. Alcoholism, clinical and experimental research, 44(6), 1189-1191. https://doi.org/10.1111/acer.14346
Haass-Koffler, Carolina L. "Protein Tyrosine Phosphatase β/ζ and Alcohol Use Disorder: A Commentary." Alcoholism, clinical and experimental research vol. 44,6 (2020): 1189-1191. doi: https://doi.org/10.1111/acer.14346
Haass-Koffler CL. Protein Tyrosine Phosphatase β/ζ and Alcohol Use Disorder: A Commentary. Alcohol Clin Exp Res. 2020 Jun;44(6):1189-1191. doi: 10.1111/acer.14346. Epub 2020 May 18. PMID: 32343842; PMCID: PMC7486965.
Copy Download .nbib Format: NLM
Serum Insulin Levels Are Reduced by Intravenous Ghrelin Administration but Do Not Correlate with Alcohol Craving in Alcohol-Dependent Individuals.

The international journal of neuropsychopharmacology

Haass-Koffler CL, Giovenco DE, Lee MR, Zywiak WH, de la Monte SM, Kenna GA, Swift RM, Leggio L.
PMID: 27207912
Int J Neuropsychopharmacol. 2016 May 10;19(10). doi: 10.1093/ijnp/pyw048.

BACKGROUND: Increasing evidence supports a role for appetite-regulating pathways like ghrelin, insulin, and leptin in alcoholism. We previously reported that intravenous (i.v.) exogenous ghrelin increases alcohol craving. We also reported i.v. ghrelin reduces endogenous serum leptin, whose levels, in...

Cite
Haass-Koffler CL, Giovenco DE, Lee MR, et al. Serum Insulin Levels Are Reduced by Intravenous Ghrelin Administration but Do Not Correlate with Alcohol Craving in Alcohol-Dependent Individuals. Int J Neuropsychopharmacol. 2016;19(10)doi: 10.1093/ijnp/pyw048.
Haass-Koffler, C. L., Giovenco, D. E., Lee, M. R., Zywiak, W. H., de la Monte, S. M., Kenna, G. A., Swift, R. M., & Leggio, L. (2016). Serum Insulin Levels Are Reduced by Intravenous Ghrelin Administration but Do Not Correlate with Alcohol Craving in Alcohol-Dependent Individuals. The international journal of neuropsychopharmacology, 19(10), . https://doi.org/10.1093/ijnp/pyw048
Haass-Koffler, Carolina L, et al. "Serum Insulin Levels Are Reduced by Intravenous Ghrelin Administration but Do Not Correlate with Alcohol Craving in Alcohol-Dependent Individuals." The international journal of neuropsychopharmacology vol. 19,10 (2016). doi: https://doi.org/10.1093/ijnp/pyw048
Haass-Koffler CL, Giovenco DE, Lee MR, Zywiak WH, de la Monte SM, Kenna GA, Swift RM, Leggio L. Serum Insulin Levels Are Reduced by Intravenous Ghrelin Administration but Do Not Correlate with Alcohol Craving in Alcohol-Dependent Individuals. Int J Neuropsychopharmacol. 2016 May 10;19(10). doi: 10.1093/ijnp/pyw048. PMID: 27207912; PMCID: PMC5091823.
Copy Download .nbib Format: NLM
Alcohol-related changes in behaviors and characteristics from the baseline to the randomization session for treatment and non-treatment seeking participants with alcohol use disorder.

The American journal of drug and alcohol abuse

Goodyear K, Vasaturo-Kolodner TR, Kenna GA, Swift RM, Leggio L, Haass-Koffler CL.
PMID: 34582281
Am J Drug Alcohol Abuse. 2021 Nov 02;47(6):760-768. doi: 10.1080/00952990.2021.1961799. Epub 2021 Sep 28.

BACKGROUND: Participants who are enrolled in randomized controlled trials (RCTs) may be more motivated to change their behaviors after being enrolled in a study and that motivation may vary by treatment status.OBJECTIVES: The objectives of this secondary analysis were...

Cite
Goodyear K, Vasaturo-Kolodner TR, Kenna GA, et al. Alcohol-related changes in behaviors and characteristics from the baseline to the randomization session for treatment and non-treatment seeking participants with alcohol use disorder. Am J Drug Alcohol Abuse. 2021;47(6):760-768doi: 10.1080/00952990.2021.1961799.
Goodyear, K., Vasaturo-Kolodner, T. R., Kenna, G. A., Swift, R. M., Leggio, L., & Haass-Koffler, C. L. (2021). Alcohol-related changes in behaviors and characteristics from the baseline to the randomization session for treatment and non-treatment seeking participants with alcohol use disorder. The American journal of drug and alcohol abuse, 47(6), 760-768. https://doi.org/10.1080/00952990.2021.1961799
Goodyear, Kimberly, et al. "Alcohol-related changes in behaviors and characteristics from the baseline to the randomization session for treatment and non-treatment seeking participants with alcohol use disorder." The American journal of drug and alcohol abuse vol. 47,6 (2021): 760-768. doi: https://doi.org/10.1080/00952990.2021.1961799
Goodyear K, Vasaturo-Kolodner TR, Kenna GA, Swift RM, Leggio L, Haass-Koffler CL. Alcohol-related changes in behaviors and characteristics from the baseline to the randomization session for treatment and non-treatment seeking participants with alcohol use disorder. Am J Drug Alcohol Abuse. 2021 Nov 02;47(6):760-768. doi: 10.1080/00952990.2021.1961799. Epub 2021 Sep 28. PMID: 34582281; PMCID: PMC8711071.
Copy Download .nbib Format: NLM
Protein Tyrosine Phosphatase β/ζ and Alcohol Use Disorder: A Commentary.

Alcoholism, clinical and experimental research

Haass-Koffler CL.
PMID: 32343842
Alcohol Clin Exp Res. 2020 Jun;44(6):1189-1191. doi: 10.1111/acer.14346. Epub 2020 May 18.

No abstract available.

Cite
Haass-Koffler CL. Protein Tyrosine Phosphatase β/ζ and Alcohol Use Disorder: A Commentary. Alcohol Clin Exp Res. 2020;44(6):1189-1191doi: 10.1111/acer.14346.
Haass-Koffler, C. L. (2020). Protein Tyrosine Phosphatase β/ζ and Alcohol Use Disorder: A Commentary. Alcoholism, clinical and experimental research, 44(6), 1189-1191. https://doi.org/10.1111/acer.14346
Haass-Koffler, Carolina L. "Protein Tyrosine Phosphatase β/ζ and Alcohol Use Disorder: A Commentary." Alcoholism, clinical and experimental research vol. 44,6 (2020): 1189-1191. doi: https://doi.org/10.1111/acer.14346
Haass-Koffler CL. Protein Tyrosine Phosphatase β/ζ and Alcohol Use Disorder: A Commentary. Alcohol Clin Exp Res. 2020 Jun;44(6):1189-1191. doi: 10.1111/acer.14346. Epub 2020 May 18. PMID: 32343842; PMCID: PMC7486965.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries